About us Leadership History News Clinical Trials Publications Contact us Healing Reimagined Immunicom’s Immunopheresis® is designed to empower patients to best live their lives while receiving revolutionary cancer treatment.This unique immunotherapy is intended to meaningfully improve patients’ quality of life and avoid typical side-effects. Watch the video LATEST MILESTONE Terumo Blood and Cell Technologies and Immunicom Establish Agreement to Launch Breakthrough Cancer Immunotherapy Treatment in Europe Read more A transformative immunotherapy Immunicom creates novel immunotherapies designed to treat a variety of diseases using Immunicom’s breakthrough Immunopheresis® technology platform. The breakthrough Immunopheresis approach uses a therapeutic device that works outside of the body and is designed to treat cancer, inflammatory, renal, and autoimmune diseases by removing barriers from the blood that block the immune system from doing its job. Watch the How it Works Video Our Recognition European Regulatory Approval FDA Breakthrough Device Designation Designed to treat multiple diseases Worldwide clinical trials are underway at leading hospitals to evaluate Immunopheresis in several cancer types, both as a singular therapy and in combination with other treatments. More about Clinical trials Latest News View all November 16, 2021 Terumo Blood and Cell Technologies and Immunicom Establish Agreement to Launch Breakthrough Cancer Immunotherapy Treatment in Europe November 2, 2021 Immunicom Conference Highlights Innovation in Clinical Trial Design to Advance its Breakthrough Cancer Immunotherapy Platform October 7, 2021 Immunicom Hires Former FDA Clinician and Medical Device Reviewer to Rapidly Progress Launch of Novel Cancer Immunotherapy September 28, 2021 Immunicom’s Alternative Subtractive Cancer Therapy Recognized with Zoom’s Healthcare Innovation Award Our Mission To improve the quality of life for patients in a meaningful way and expedite their path to a healthy future. About us Get in touch today Let’s talk about what we can achieve together Contact us Learn more about our team Who are we Immunicom Inc. HEADQUARTERS San Diego, CA RESOURCES Terms of Use Privacy policy GET IN TOUCH Contact us Newsletter Subscription Immunicom’s Immunopheresis® therapy, including the LW-02 blood-filtering immunotherapy device, has not been approved by the US Food and Drug Administration and is an investigational therapy in all of Immunicom’s ongoing clinical research studies. Immunicom’s LW-02 blood-filtering immunotherapy device has been granted European CE Mark Certification for use in adults with advanced, refractory, triple-negative breast cancer in Europe. © 2021 — Immunicom, Inc. All Rights Reserved. We use cookies and similar technologies to enable services and functionality on our site and to understand your interaction with our service. By clicking on accept, you agree to our use of such technologies for marketing and analytics. Cookie settings Accept all